Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial

Summary

The phase II DETECT IVb trial assessed the efficacy and safety of eribulin in patients with HER2-negative metastatic breast cancer, focusing on circulating tumor cell (CTC) dynamics. The study confirmed eribulin as an effective treatment option for this high-risk population, showing a median progression-free survival of 4.6 months and a median overall survival of 13.4 months. Furthermore, CTC clearance was significantly associated with improved progression-free survival. The observed adverse events were consistent with the known safety profile of eribulin.

Critical appraisal

Clinical. This single-arm phase II trial confirms eribulin as an effective therapeutic option for HER2-negative metastatic breast cancer, particularly in pretreated patients. Median progression-free survival (4.6 months) and overall survival (13.4 months) are reported. The study highlights the prognostic role of CTCs and suggests that early CTC clearance could serve as a predictive biomarker of response to eribulin treatment, potentially justifying phase III studies to validate this biomarker. This could, in the long term (3-5 years), guide therapeutic decisions and treatment adaptation.

Molecular biology. The study utilized CellSearch® technology for circulating tumor cell (CTC) detection, a validated method for their quantification. The key discovery is that CTC dynamics, specifically their clearance, acts as a potential early response biomarker for eribulin. While CTCs are an established prognostic marker, their role as a predictive biomarker for specific treatment response is less clear. These findings support the integration of CTC monitoring into future clinical trials to stratify patients or assess therapeutic response, paving the way for clinical tests to identify patients most likely to benefit from eribulin.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology